- Home
- IDE vs CATX Comparison
IDE vs CATX Comparison
Compare IDE & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IDE | CATX |
|---|---|---|
| Founded | 2010 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.6M | 211.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IDE | CATX |
|---|---|---|
| Price | $12.28 | $2.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 33.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.61 | $1.60 |
| 52 Week High | $10.46 | $5.39 |
Technical Indicators
Market Signals| Indicator | IDE | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 53.90 |
| Support Level | $12.05 | $2.67 |
| Resistance Level | $12.10 | $2.88 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 84.09 | 64.44 |
Price Performance
Historical ComparisonAbout IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.